Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 6/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8688500 | 1.00 | LMNA (0.39) | LMNAMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL8688535 | 1.00 | LMNA (0.39) | LMNAMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL5963881 | 0.97 | SMN1; SMN2 (0.36) | LMNAMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL3836906 | 0.89 | — | — | |
| SCHEMBL16440537 | 0.87 | LMNA (0.34) | LMNAMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL20483089 | 0.86 | — | — | |
| SCHEMBL16295146 | 0.86 | — | — | |
| SCHEMBL9284273 | 0.86 | — | — | |
| SCHEMBL16294338 | 0.86 | — | — | |
| SCHEMBL30959777 | 0.84 | GPR84 (0.59) | LMNAMEN1KMT2AALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8246854-B2 | Organic catalyst with enhanced solubility | THE PROCTER & GAMBLE COMPANY (US) | 2012-08-21 | — | — | US | disclosed |
| US-20110253931-A1 | ORGANIC CATALYST WITH ENHANCED SOLUBILITY | MIRACLE GREGORY SCOT | 2011-10-20 | — | — | US | disclosed |
| US-7994109-B2 | Organic catalyst with enhanced solubility | THE PROCTER & GAMBLE COMPANY (US) | 2011-08-09 | — | — | US | disclosed |
| US-20090143272-A1 | ORGANIC CATALYST WITH ENHANCED SOLUBILITY | MIRACLE GREGORY SCOT | 2009-06-04 | — | — | US | disclosed |
| US-7507700-B2 | Organic catalyst with enhanced solubility | THE PROCTER & GAMBLE COMPANY (US) | 2009-03-24 | — | — | US | disclosed |
| US-7169744-B2 | Organic catalyst with enhanced solubility | PROCTER & GAMBLE COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| US-20060211590-A1 | Organic catalyst with enhanced solubility | MIRACLE GREGORY S | 2006-09-21 | — | — | US | disclosed |
| EP-1509503-A2 | IMINIUM SALTS IN CLEANING COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040018951-A1 | Organic catalyst with enhanced solubility | THE PROCTER & GAMBLE CO | 2004-01-29 | — | — | US | disclosed |
| WO-2003104199-A2 | ORGANIC CATAYST WITH ENHANCED SOLUBILITY | THE PROCTER & GAMBLE COMPANY (US) | 2003-12-18 | — | — | WO | disclosed |
| US-5817879-A | PEPTIDE ANTAGONIST | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1998-10-06 | — | — | US | disclosed |
| US-5550251-A | CROSSREACTIVE WITH PEPTIDES BOUND BY G-PROTEIN LINKED RECEPTORS; USED AS THERAPEUTICAL, DIAGNOSTIC, AND PROPHYLITIC | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 1996-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110253931-A1 | ORGANIC CATALYST WITH ENHANCED SOLUBILITY | OCIAD2, ICOSLG, OCIAD1 | LMNA 4400/4885MEN1 2283/4885KMT2A 1708/4885 |
| US-20060211590-A1 | Organic catalyst with enhanced solubility | OCIAD2, ICOSLG, OCIAD1 | LMNA 4400/4885MEN1 2283/4885KMT2A 1708/4885 |
| US-20090143272-A1 | ORGANIC CATALYST WITH ENHANCED SOLUBILITY | OCIAD2, ICOSLG, OCIAD1 | LMNA 4400/4885MEN1 2283/4885KMT2A 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.